Prevalence and Significance of Restless Legs Syndrome in Patients with Coronary Artery Disease
Restless legs syndrome (RLS), characterized by leg restlessness and dysesthesia predominantly at night and at rest, disrupts sleep and quality of life. The reported prevalence of RLS is 2-5%. Although a relationship between RLS and coronary artery disease has been suggested, the prevalence and clinical significance of RLS in coronary artery disease patients remain unknown. We enrolled coronary artery disease patients undergoing percutaneous coronary intervention. Patients with RLS were identified according to international criteria.
Purpose of review Summarize the effects of opioids on sleep including sleep architecture, sleep disordered breathing (SDB) and restless legs syndrome. Recent findings Opioids are associated with the development of central sleep apnea (CSA) and ataxic breathing. Recent reports suggest that adaptive servo-ventilation may be an effective treatment for CSA associated with opioids. Summary Opioids have multiple effects on sleep, sleep architecture and SDB. Although originally described with methadone use, most commonly used opioids have also been shown to affect sleep. In patients on chronic methadone, sleep architectur...
ConclusionThe prevalence of RLS among this sample of adult patients with sickle cell anemia was much higher than that previously reported for the general Turkish population. The presence of RLS was an important cause of sleep disturbance in these adult patients with SCA.
CONCLUSION: The prevalence of RLS among this sample of adult patients with sickle cell anemia was much higher than that previously reported for the general Turkish population. The presence of RLS was an important cause of sleep disturbance in these adult patients with SCA. PMID: 33029692 [PubMed - as supplied by publisher]
CONCLUSION: A significant relationship was detected between RLS and increased serum hepcidin levels in chronic HD patients, and uncontrolled diabetes was noted to contribute to this association. PMID: 33029690 [PubMed - as supplied by publisher]
AbstractParkinson ’s disease (PD) is an alpha-synucleinopathy that leads to prominent motor symptoms including tremor, bradykinesia, and postural instability. Nonmotor symptoms including autonomic, neurocognitive, psychiatric symptoms, and sleep disturbances are also seen frequently in PD. The impact of PD on sleep is related to motor and nonmotor symptoms, in addition to the disruption of the pathways regulating sleep by central nervous system pathology. Rapid eye movement sleep behavior disorder is a parasomnia that can lead to self-injury and/or injury to partners at night. Restless legs syndrome is a subj ective ...
ConclusionA significant relationship was detected between RLS and increased serum hepcidin levels in chronic HD patients, and uncontrolled diabetes was noted to contribute to this association.
Restless legs syndrome (RLS) is a sensorimotor disorder defined by an uncontrollable “urge to move” the limbs during rest, that is temporarily relieved by movement and cannot be explained by other medical or behavioural conditions(1). Individuals with end stage kidney disease (ESKD) are known to have a high symptom burden(2-4), which often goes unrecognised(5). Uraemic RLS is re ported to affect almost 30% of ESKD patients(6, 7) which significantly reduces quality of life and impacts upon sleep quality, ability to dialyse(8) and mortality(7, 8).
Conclusion: This systematic review will provide evidence of whether Shaoyao Gancao Tang is an effective and safe intervention for RLS.
Conclusion: This study will provide a high-quality evidence to evaluate the efficacy and adverse reactions of acupuncture and related techniques for RLS. PROSPERO registration number: CRD42020157957.
This article reviews the etiology, implications and management of sleep disturbances in PD, such as excessive daytime sleepiness, insomnia, restless legs syndrome, rapid eye movement sleep behavior disorder and SDB. We also briefly explore the potential role of sleep disorders, including SDB, in the progression of neurodegeneration. PMID: 32956712 [PubMed - as supplied by publisher]